Glomerulonephritis Clinical Trials

A listing of Glomerulonephritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

)patients with vasculitis or glomerulonephritis. Approximately 1500 participants will be randomised to active treatment or placebo, stratified by PROTECT sub-population, age and participating sites

  • 0 views
  • 11 May, 2021
  • 1 location
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis

Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

  • 0 views
  • 19 Jun, 2021
  • 38 locations
Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

the structures in the body more clearly. If this technique is successful, the need for DMSA studies may be avoided to diagnose or evaluate kidney scarring. DMSA is a more expensive test, causes

  • 0 views
  • 24 Jan, 2021
Atrasentan in Patients With IgA Nephropathy

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

nephropathy
renal function
  • 0 views
  • 01 Aug, 2021
  • 58 locations
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of LNP023 at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

nephropathy
hbeag
treatment regimen
proteinuria
mammogram
  • 0 views
  • 01 Aug, 2021
  • 100 locations
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.

immunoglobulin a
proteinuria
immunoglobulins
glomerular filtration rate
  • 243 views
  • 22 Jan, 2021
  • 29 locations
Efficacy Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)

This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy, safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy

remission
enzyme inhibitor
kidney biopsy
proteinuria
nephropathy
  • 0 views
  • 12 Jun, 2021
  • 16 locations
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.

focal segmental glomerulosclerosis
tubulointerstitial fibrosis
immunosuppressive agents
total protein
glomerular filtration rate
  • 226 views
  • 02 Aug, 2021
  • 104 locations
Study of Safety Efficacy and Tolerability of Secukinumab Versus Placebo in Combination With SoC Therapy in Patients With Active Lupus Nephritis

The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features).

urinary sediment
nephritis
mammogram
glomerular filtration rate
  • 37 views
  • 30 Jul, 2021
  • 123 locations
A Study of Guselkumab in Participants With Active Lupus Nephritis

The purpose of this study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN).

antinuclear antibody
angiotensin receptor blockers
mycophenolate
prednisone
mycophenolic acid
  • 0 views
  • 01 Aug, 2021
  • 69 locations